These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 11157685)

  • 1. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.
    Freeman DJ; Norrie J; Sattar N; Neely RD; Cobbe SM; Ford I; Isles C; Lorimer AR; Macfarlane PW; McKillop JH; Packard CJ; Shepherd J; Gaw A
    Circulation; 2001 Jan; 103(3):357-62. PubMed ID: 11157685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS).
    Streja L; Packard CJ; Shepherd J; Cobbe S; Ford I;
    Am J Cardiol; 2002 Oct; 90(7):731-6. PubMed ID: 12356386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group.
    Am J Cardiol; 1997 Mar; 79(6):756-62. PubMed ID: 9070554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project.
    Sacks FM; Tonkin AM; Shepherd J; Braunwald E; Cobbe S; Hawkins CM; Keech A; Packard C; Simes J; Byington R; Furberg CD
    Circulation; 2000 Oct; 102(16):1893-900. PubMed ID: 11034935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study].
    Comaschi MA; Menozzi F
    Ital Heart J Suppl; 2001 May; 2(5):556-8. PubMed ID: 11388336
    [No Abstract]   [Full Text] [Related]  

  • 6. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.
    Keech A; Colquhoun D; Best J; Kirby A; Simes RJ; Hunt D; Hague W; Beller E; Arulchelvam M; Baker J; Tonkin A;
    Diabetes Care; 2003 Oct; 26(10):2713-21. PubMed ID: 14514569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.
    Sattar N; Gaw A; Scherbakova O; Ford I; O'Reilly DS; Haffner SM; Isles C; Macfarlane PW; Packard CJ; Cobbe SM; Shepherd J
    Circulation; 2003 Jul; 108(4):414-9. PubMed ID: 12860911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    McEvoy JW; Margey R; Blake GJ
    N Engl J Med; 2008 Jan; 358(2):193; author reply 194-5. PubMed ID: 18184967
    [No Abstract]   [Full Text] [Related]  

  • 9. Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS).
    Am J Cardiol; 1995 Nov; 76(12):899-905. PubMed ID: 7484829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.
    Goldberg RB; Mellies MJ; Sacks FM; Moyé LA; Howard BV; Howard WJ; Davis BR; Cole TG; Pfeffer MA; Braunwald E
    Circulation; 1998 Dec; 98(23):2513-9. PubMed ID: 9843456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study.
    J Am Coll Cardiol; 1999 Mar; 33(4):909-15. PubMed ID: 10091815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.
    Lowe G; Rumley A; Norrie J; Ford I; Shepherd J; Cobbe S; Macfarlane P; Packard C
    Thromb Haemost; 2000 Oct; 84(4):553-8. PubMed ID: 11057849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cardiovascular event reduction tool (CERT)--a simplified cardiac risk prediction model developed from the West of Scotland Coronary Prevention Study (WOSCOPS).
    L'Italien G; Ford I; Norrie J; LaPuerta P; Ehreth J; Jackson J; Shepherd J
    Am J Cardiol; 2000 Mar; 85(6):720-4. PubMed ID: 12000046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study.
    Shepherd J; Gaw A;
    Med Princ Pract; 2002; 11 Suppl 2():17-30. PubMed ID: 12444307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.
    Caro J; Klittich W; McGuire A; Ford I; Norrie J; Pettitt D; McMurray J; Shepherd J
    BMJ; 1997 Dec; 315(7122):1577-82. PubMed ID: 9437275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin.
    West MJ; White HD; Simes RJ; Kirby A; Watson JD; Anderson NE; Hankey GJ; Wonders S; Hunt D; Tonkin AM
    J Hypertens; 2002 Dec; 20(12):2513-7. PubMed ID: 12473877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pravastatin and risk factor modification in patients with moderate primary hypercholesterolaemia.
    Morris R; Robinson G; Tilyard M; Gurr E
    N Z Med J; 1996 Aug; 109(1028):319-22. PubMed ID: 8816723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).
    Circulation; 1998 Apr; 97(15):1440-5. PubMed ID: 9576423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.